Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries

BACKGROUND: Rituximab is a standard treatment for non-Hodgkin lymphoma. The SABRINA trial (NCT01200758) showed that a subcutaneous (SC) rituximab formulation did not compromise efficacy or safety compared with intravenous (IV) infusion. We aimed to quantify active healthcare professional (HCP) time...

Descripción completa

Detalles Bibliográficos
Autores principales: De Cock, Erwin, Kritikou, Persefoni, Sandoval, Mariana, Tao, Sunning, Wiesner, Christof, Carella, Angelo Michele, Ngoh, Charles, Waterboer, Tim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4928781/
https://www.ncbi.nlm.nih.gov/pubmed/27362533
http://dx.doi.org/10.1371/journal.pone.0157957

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4928781/
https://www.ncbi.nlm.nih.gov/pubmed/27362533
http://dx.doi.org/10.1371/journal.pone.0157957

Ejemplares similares